AMAG Inks $7.5M Deal In Suit Over Preterm-Birth Drug

By Rae Ann Varona · May 8, 2025, 10:37 PM EDT

AMAG Pharmaceuticals has agreed to pay $7.5 million to resolve a group of women's proposed class action accusing it of misleading consumers into believing one of its drugs reduced the risk...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

ZAMFIROVA v. AMAG PHARMACEUTICALS, INC.

Case Number

Court

New Jersey

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

January 03, 2020

Recent Articles By Rae

May 01, 2025
DaVita Hit With Class Actions Over Ransomware Attack
April 29, 2025
Ohio Justices Reinstate Trans Care Limits During AG's Appeal
April 25, 2025
HHS Sued Over Withholding Of $65.8M In Title X Funding
March 24, 2025
Period App Users Get $3.5M In Privacy Deal With Analytics Co.
March 21, 2025
Judge Says Anti-Abortion Group's Clinic Blockades Are Illegal
March 17, 2025
Gutting USAID Threatens US Credibility, 22 Ex-Officials Say
March 03, 2025
Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells
February 07, 2025
CFPB's Medical Debt Rule Halted For 90 Days By Texas Judge
February 04, 2025
9th Circ. Revives FCA Suit Over Military Meds Deliveries
January 31, 2025
New York Scores Win In Reproductive Rights Labor Law Suit